EGFR and lung cancer: Recently, target therapies, for instance, inhibiting the epidermal growth factor receptor (EGFR) through tyrosine kinase inhibitors (TKIs) [6] and immune checkpoint inhibitors, have been triumphantly used in clinical diagnose and treatments despite that traditional therapeutic strategies have been tremendously improved while the survival rate of lung cancer combined remains extremely low [2].